Patients with inflammatory bowel disease (IBD) often exhibit gut microbiota dysbiosis and are predisposed to psychiatric disorders such as anxiety and depression. Consequently, developing novel oral probiotic therapies to address intestinal inflammation, microbiota dysbiosis, and psychiatric comorbidities is essential for managing IBD. Here, we propose a probiotic spore‐based bioresponsive system (BCS‐Que@ApNPs) fabricated by thioketone linkage of Quercetin‐loaded
Antheraea pernyi (AP)
silk fibroin nanoparticles (Que@ApNPs) to the
Bacillus coagulans
spores (BCS). The
AP
silk fibroin with arginine‐glycine‐aspartate (RGD) tripeptides in Que@ApNPs nanoparticles is critical for bioresponsive targeting Quercetin (Que) delivery to the inflamed intestinal epithelium. BCS could effectively shield probiotics from gastric acid‐induced degradation, maintaining their bioactivity in the intestinal tract, where they modulate the gut microbiota and preserve the integrity of the intestinal barrier. Notably, BCS‐Que@ApNPs can inhibit neuroinflammation and enhance hippocampal neural plasticity in the IBD mice model. Additionally, behavioral test results reveal that BCS‐Que@ApNPs alleviate IBD‐associated anxiety and depressive behaviors. This work provides a bioresponsive probiotic drug hybrid delivery system, highlighting a gut‐brain axis intervention therapeutic strategy for individuals diagnosed with IBD and its associated anxiety and depression.
A comprehensive overview of probiotic-derived EVs, including their biogenesis, classification, and molecular composition, is provided, with a focus on barrier regulation, immune modulation, and microbial homeostasis in IBD.
H. Jeon, A. Choe, Seong-Eun Kim· International Journal of Nan...· 0 citations
Inflammatory bowel disease (IBD) is a complex intestinal disorder for which effective treatment options remain limited. The modulation of gut microbiota balance using probiotics holds promise as a therapeutic approach to restore intestinal microenvironment homeostasis. However, the clinical translation of conventional...
Fan Yang, Li-Na He, Xiang Lin et al.· ACS Synthetic Biology· 0 citations
Inflammatory bowel disease (IBD) is driven by a complex interplay among epithelial barrier breakdown, immune dysregulation, microbial dysbiosis, and redox imbalance. Curcumin, a major curcuminoid from turmeric (Curcuma longa L.) and a widely used food ingredient, has attracted sustained interest as a dietary bioactive...
J. Pu, Ying-Lin Ding, Guo Chen et al.· Food & Function· 1 citation
To overcome biopharmaceutical bottlenecks, an overview of nanozyme-based intelligent delivery platforms tailored for the inflamed gut are provided, covering endogenous/exogenous stimuli-responsive, biomimetic, and microbiota-mediated systems.